1. Home
  2. YJ vs KZIA Comparison

YJ vs KZIA Comparison

Compare YJ & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunji Inc. American Depository Shares

YJ

Yunji Inc. American Depository Shares

HOLD

Current Price

$1.99

Market Cap

13.3M

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$11.34

Market Cap

186.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YJ
KZIA
Founded
2015
1994
Country
China
Australia
Employees
N/A
6
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3M
186.7M
IPO Year
2019
2002

Fundamental Metrics

Financial Performance
Metric
YJ
KZIA
Price
$1.99
$11.34
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.50
AVG Volume (30 Days)
2.5M
263.3K
Earning Date
03-27-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$4.86
52 Week High
$13.97
$17.40

Technical Indicators

Market Signals
Indicator
YJ
KZIA
Relative Strength Index (RSI) 45.49 38.77
Support Level $1.42 $7.25
Resistance Level $2.33 $14.85
Average True Range (ATR) 0.33 1.15
MACD -0.14 -0.30
Stochastic Oscillator 2.04 5.04

Price Performance

Historical Comparison
YJ
KZIA

About YJ Yunji Inc. American Depository Shares

Yunji Inc is a social e-commerce platform in China using a membership-based model that leverages the power of social interaction. The group offers high-quality products at attractive prices and incentivizes members to promote its platform and share products with their social contacts. It empowers prime emerging brands and manufacturers with a deep understanding of market trends and customer behavior to produce high-quality products to meet the demands of members. The company also developed several private labels in the mass consumption field, which are sold on its own platform as well as offered and sold through external channels. It operates in the PRC, and substantially all the Group's revenue is derived from within the PRC.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: